Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Chlorobutanol is a colorless to white crystalline compound with a camphoraceous odor and taste. It is an alcohol-based preservative widely used in pharmaceutical solutions—especially injectables and ophthalmic preparations—due to its antibacterial and antifungal properties[5][3][7]. Chlorobutanol also exhibits sedative-hypnotic effects and weak local anesthetic actions similar to chloral hydrate[5][4]. Its mechanism of action includes disruption of cell membrane lipids leading to increased permeability and cell lysis; it can inhibit voltage-gated sodium channels (Nav 1.2) in neurons at concentrations lower than those used for preservation[8][4]. Additionally, it inhibits hERG potassium channels at millimolar concentrations[6], which may contribute to its negative inotropic effects on cardiac tissue. Chlorobutanol is not commonly used as a systemic sedative due to its long terminal half-life (about 37 days), which leads to accumulation with repeated dosing[2]. It was first synthesized by Conrad Willgerodt in 1881.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on chlorobutanol.